Resveratrol is a class IA phosphoinositide 3-kinase inhibitor

Biochemical Journal

Volumn 406, Issue 3, 2007, Pages 511-518

  Fröjdö, Sara ^a   Cozzone, Delphine ^a   Vidal, Hubert ^a   Pirola, Luciano ^a  

^a UNIVERSITÉ LYON 1   (France)

Author keywords

Deacetylase; Human primary myotube; Insulin signalling; Phosphoinositide 3 kinase; Resveratrol; Sirtuin

Indexed keywords

INSULIN; PHENOLS; YEAST;

DEACETYLASE; HUMAN PRIMARY MYOTUBE; INSULIN SIGNALING; PHOSPHOINOSITIDE 3-KINASE; RESVERATROL; SIRTUIN;

ENZYMES;

PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE INHIBITOR; RESVERATROL; SIRTUIN;

ADIPOCYTE; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MYOTUBE; NONHUMAN; PRIORITY JOURNAL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOSINE TRIPHOSPHATE; ANIMALS; CELLS, CULTURED; ENZYME INHIBITORS; HUMANS; INSULIN; MICE; MUSCLE FIBERS; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RIBONUCLEOTIDE REDUCTASES; SIGNAL TRANSDUCTION; SIRTUINS; STILBENES;

METAZOA; MUS;

EID: 34548730196     PISSN: 02646021     EISSN: None     Source Type: Journal    
DOI: 10.1042/BJ20070236     Document Type: Article

References (49)

1. Baur, J. A. and Sinclair, D. A. (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov. 5, 493-506
2. Jang, M., Cai, L., Udeani, G. O., Slowing, K. V., Thomas, C. F., Beecher, C. W., Fong, H. H., Farnsworth, N. R., Kinghorn, A. D., Mehta, R. G. et al. (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275, 218-220
3. Sexton, E., Van Themsche, C., LeBlanc, K., Parent, S., Lemoine, P. and Asselin, E. (2006) Resveratrol interferes with AKT activity and triggers apoptosis in human uterine cancer cells. Mol. Cancer 5, 45
4. Faber, A. C., Dufort, F. J., Blair, D., Wagner, D., Roberts, M. F. and Chiles, T. C. (2006) Inhibition of phosphatidylinositol 3-kinase-mediated glucose metabolism coincides with resveratrol-induced cell cycle arrest in human diffuse large B-cell lymphomas. Biochem. Pharmacol. 72, 1246-1256
5. Yang, T., Fu, M., Pestell, R. and Sauve, A. A. (2006) SIRT1 and endocrine signaling. Trends Endocrinol. Metab. 17, 186-191
6. Vaziri, H., Dessain, S. K., Ng Eaton, E., Imai, S. I., Frye, R. A., Pandita, T. K., Guarente, L. and Weinberg, R. A. (2001) hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107, 149-159
7. Brunet, A., Sweeney, L. B., Sturgill, J. F., Chua, K. F., Greer, P. L., Lin, Y., Tran, H., Ross, S. E., Mostoslavsky, R., Cohen, H. Y. et al. (2004) Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303, 2011-2015
8. Guarente, L. and Kenyon, C. (2000) Genetic pathways that regulate ageing in model organisms. Nature 408, 255-262
9. Howitz, K. T., Bitterman, K. J., Cohen, H. Y., Lamming, D. W., Lavu, S., Wood, J. G., Zipkin, R. E., Chung, P., Kisielewski, A., Zhang, L. L. et al. (2003) Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425, 191-196
10. Wood, J. G., Rogina, B., Lavu, S., Howitz, K., Helfand, S. L., Tatar, M. and Sinclair, D. (2004) Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 430, 686-289
11. Baur, J. A., Pearson, K. J., Price, N. L., Jamieson, H. A., Lerin, C., Kalra, A., Prabhu, V. V., Allard, J. S., Lopez-Lluch, G., Lewis, K. et al. (2006) Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444, 337-342
12. Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Milne, J., Lambert, P., Elliott, P. et al. (2006) Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α. Cell 127, 1109-1122
13. Kaeberlein, M., McDonagh, T., Heltweg, B., Hixon, J., Westman, E. A., Caldwell, S. D., Napper, A., Curtis, R., DiStefano, P. S., Fields, S. et al. (2005) Substrate-specific activation of sirtuins by resveratrol. J. Biol. Chem. 280, 17038-17045
14. Borra, M. T., Smith, B. C. and Denu, J. M. (2005) Mechanism of human SIRT1 activation by resveratrol. J. Biol. Chem. 280, 17187-17195
15. Kaeberlein, M., Powers, III, R. W., Steffen, K. K., Westman, E. A., Hu, D., Dang, N., Kerr, E. O., Kirkland, K. T., Fields, S. and Kennedy, B. K. (2005) Regulation of yeast replicative life span by TOR and Sch9 in response to nutrients Science 310, 1193-1196
16. Fabrizio, P., Pozza, F., Pletcher, S. D., Gendron, C. M. and Longo, V. D. (2001) Regulation of longevity and stress resistance by Sch9 in yeast. Science 292, 288-290
17. Holzenberger, M., Dupont, J., Ducos, B., Leneuve, P., Geloen, A., Even, P. C., Cervera, P. and Le Bouc, Y. (2003) IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature 421, 182-187
18. Bluher, M., Kahn, B. B. and Kahn, C. R. (2003) Extended longevity in mice lacking the insulin receptor in adipose tissue. Science 299, 572-574
19. Berdichevsky, A., Viswanathan, M., Horvitz, H. R. and Guarente, L. (2006) C. elegans SIR-2.1 interacts with 14-3-3 proteins to activate DAF-16 and extend life span. Cell 125, 1165-1177
20. Rodgers, J. T., Lerin, C., Haas, W., Gygi, S. P., Spiegelman, B. M. and Puigserver, P. (2005) Nutrient control of glucose homeostasis through a complex of PGC-1α and SIRT1. Nature 434, 113-118
21. Picard, F., Kurtev, M., Chung, N., Topark-Ngarm, A., Senawong, T., Machado De Oliveira, R., Leid, M., McBurney, M. W. and Guarente, L. (2004) Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-γ. Nature 429, 771-776
22. Bordone, L., Motta, M. C., Picard, F., Robinson, A., Jhala, U. S., Apfeld, J., McDonagh, T., Lemieux, M., McBurney, M., Szilvasi, A. et al. (2006) Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic β cells. PLoS Biol. 4, e31
23. Moynihan, K. A., Grimm, A. A., Plueger, M. M., Bemal-Mizrachi, E., Ford, E., Cras-Meneur, C., Permutt, M. A. and Imai, S. (2005) Increased dosage of mammalian Sir2 in pancreatic β cells enhances glucose-stimulated insulin secretion in mice. Cell Metab. 2, 105-117
24. Wymann, M. P., Zvelebil, M. and Laffargue, M. (2003) Phosphoinositide 3-kinase signalling - which way to target? Trends Pharmacol. Sci. 24, 366-376
25. Vanhaesebroeck, B. and Alessi, D. R. (2000) The PI3K-PDK1 connection: more than just a road to PKB. Biochem. J. 346, 561-576
26. Pirola, L., Bonnafous, S., Johnston, A. M., Chaussade, C., Portis, F. and Van Obberghen, E. (2003) Phosphoinositide 3-kinase-mediated reduction of insulin receptor substrate-1/2 protein expression via different mechanisms contributes to the insulin-induced desensitization of its signaling pathways in L6 muscle cells J. Biol. Chem. 278, 15641-15651
27. Wymann, M. P., Bulgarelli-Leva, G., Zvelebil, M. J., Pirola, L., Vanhaesebroeck, B., Waterfield, M. D. and Panayotou, G. (1996) Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol. Cell. Biol. 16, 1722-1733
28. Czupalla, C., Culo, M., Muller, E. C., Brock, C., Reusch, H. P., Spicher, K., Krause, E. and Nurnberg, B. (2003) Identification and characterization of the autophosphorylation sites of phosphoinositide 3-kinase isoforms β and γ. J. Biol. Chem. 278, 11536-11545
29. Bondeva, T., Pirola, L., Bulgarelli-Leva, G., Rubio, I., Wetzker, R. and Wymann, M. P. (1998) Bifurcation of lipid and protein kinase signals of PI3Kγ to the protein kinases PKB and MAPK. Science 282, 293-296
30. Roques, M. and Vidal, H. (1999) A phosphatidylinositol 3-kinase/p70 ribosomal S6 protein kinase pathway is required for the regulation by insulin of the p85α regulatory subunit of phosphatidylinositol 3-kinase gene expression in human muscle cells. J. Biol. Chem. 274, 34005-34010
31. Orlicky, D. J., DeGregori, J. and Schaack, J. (2001) Construction of stable coxsackievirus and adenovirus receptor-expressing 3T3-L1 cells. J. Lipid Res. 42, 910-915
32. White, M. F. (1997) The insulin signalling system and the IRS proteins. Diabetologia 40, S2-S17
33. Bryant, N. J., Govers, R. and James, D. E. (2002) Regulated transport of the glucose transporter GLUT4. Nat. Rev. Mol. Cell Biol. 3, 267-277
34. Park, J. B. (2001) Inhibition of glucose and dehydroascorbic acid uptakes by resveratrol in human transformed myelocytic cells. J. Nat. Prod. 64, 381-384
35. Kosaki, A., Yamada, K., Suga, J., Otaka, A. and Kuzuya, H. (1998) 14-3-3β protein associates with insulin receptor substrate 1 and decreases insulin-stimulated phosphatidylinositol 3′-kinase activity in 3T3L1 adipocytes. J. Biol. Chem. 273, 940-944
36. Ogihara, T., Isobe, T., Ichimura, T., Taoka, M., Funaki, M., Sakoda, H., Onishi, Y., Inukai, K., Anai, M., Fukushima, Y. et al. (1997) 14-3-3 protein binds to insulin receptor substrate-1, one of the binding sites of which is in the phosphotyrosine binding domain. J. Biol. Chem. 272, 25267-25274
37. Dhand, R., Hiles, I., Panayotou, G., Roche, S., Fry, M. J., Gout, I., Totty, N. F., Truong, O., Vicendo, P., Yonezawa, K. et al. (1994) PI3-kinase is a dual specificity enzyme: autoregulation by an intrinsic protein-serine kinase activity. EMBO J. 13, 522-533
38. Vlahos, C. J., Matter, W. F., Hui, K. Y. and Brown, R. F. (1994) A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl- 4H-1-benzopyran-4-one (LY294002). J. Biol. Chem. 269, 5241-5248
39. Longo, V. D. and Kennedy, B. K. (2006) Sirtuins in aging and age-related disease. Cell 126, 257-268
40. Valenzano, D. R., Terzibasi, E., Genade, T., Cattaneo, A., Domenici, L. and Cellerino, A. (2006) Resveratrol prolongs lifespan and retards the onset of age-related markers in a short-lived vertebrate. Curr. Biol. 16, 296-300
41. Kundu, J. K. and Surh, Y. J. (2004) Molecular basis of chemoprevention by resveratrol: NF-kappaB and AP-1 as potential targets. Mutat, Res. 555, 65-80
42. Zhang, J. (2006) Resveratrol inhibits insulin responses in a SirT1-independent pathway. Biochem. J. 397, 519-527
43. Srivastava, A. K. (1985) Inhibition of phosphorylase kinase, and tyrosine protein kinase activities by quercetin. Biochem. Biophys. Res. Commun. 131, 1-5
44. Walker, E. H., Pacold, M. E., Perisic, O., Stephens, L., Hawkins, P. T., Wymann, M. P. and Williams, R. L. (2000) Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol. Cell 6, 909-919
45. Sicheri, F., Moarefi, I. and Kuriyan, J. (1997) Crystal structure of the Src family tyrosine kinase Hck. Nature 385, 602-609
46. Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y. and Mills, G. B. (2005) Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 4, 988-1004
47. Knight, Z. A., Gonzalez, B., Feldman, M. E., Zunder, E. R., Goldenberg, D. D., Williams, O., Loewith, R., Stokoe, D., Balla, A., Toth, B. et al. (2006) A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling. Cell 125, 733-747
48. Jackson, S. P., Schoenwaelder, S. M., Goncalves, I., Nesbitt, W. S., Yap, C. L., Wright, C. E., Kenche, V., Anderson, K. E., Dopheide, S. M., Yuan, Y. et al. (2005) PI3-kinase p110β: a new target for antithrombotic therapy. Nat. Med. 11, 507-514
49. Camps, M., Ruckle, T., Ji, H., Ardissone, V., Rintelen, F., Shaw, J., Ferrandi, C., Chabert, C., Gillieron, C., Francon, B. et al. (2005) Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat. Med. 11, 936-943